Tango Therapeutics Business Summary

Tango Therapeutics, Inc. (TNGX) is a clinical-stage biotechnology company that generates revenue primarily through high-value strategic collaborations and milestone-based licensing agreements, most notably a multi-program partnership with Gilead Sciences that yielded $62.4 million in collaboration revenue for fiscal year 2025. The company operates within the precision oncology segment, leveraging a proprietary functional genomics platform to develop synthetic lethal therapies that target genetic vulnerabilities in cancer cells, specifically those with MTAP deletions. Its primary business focus is the clinical advancement of its lead MTA-cooperative PRMT5 inhibitors: vopimetostat (TNG462), which is entering pivotal trials for pancreatic cancer in 2026, and the brain-penetrant TNG456 for glioblastoma. Tango competes directly with Prelude Therapeutics, Repare Therapeutics, IDEAYA Biosciences, and Bristol-Myers Squibb, positioning itself as a frontrunner in the PRMT5 inhibitor class by transitioning from early-stage discovery to registrational clinical execution. In January 2026, Tango underwent a strategic leadership transition, appointing Malte Peters, M.D., as President and CEO. Dr. Peters brings a distinguished pedigree from his previous roles as Chief R&D Officer at MorphoSys AG and senior leadership positions at Sandoz and Novartis. He succeeds founding CEO Barbara Weber, M.D., a former Novartis and GSK executive and Third Rock Ventures partner, who now serves as Executive Chair. The executive team is further bolstered by Adam Crystal, M.D., Ph.D. (President of R&D), formerly CMO of C4 Therapeutics, and Michael Palmieri, Ph.D., who serves as Chief Technical Operations Officer. The company was co-founded by Alexis Borisy of Third Rock Ventures alongside a world-class scientific advisory board including Nobel laureate William Kaelin and Alan Ashworth. Tango maintains a robust institutional backing from investors such as Nextech, Boxer Capital, and Bain Capital Life Sciences, supporting a cash runway that extends into 2028.